GH.O Hits 52-Week High Amid Market Surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 24 Nov 25
Source: Coinmarketcap
Shares of GH.O reached a new 52-week high today, reflecting strong investor sentiment and positive market conditions. The stock's upward momentum is underscored by robust performance in the broader market, particularly following the acquisition of Exact Sciences Corporation by Abbott Laboratories, which surged nearly 49%. This acquisition has sparked increased interest in related sectors, contributing to GH.O's impressive gains. Analysts suggest that the bullish trend may continue as more companies report favorable financial results and receive upgrades from analysts, further enhancing market confidence.
Analyst Views on GH
Wall Street analysts forecast GH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GH is 124.69 USD with a low forecast of 105.00 USD and a high forecast of 155.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 109.730
Low
105.00
Averages
124.69
High
155.00
Current: 109.730
Low
105.00
Averages
124.69
High
155.00
About GH
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.





